Venetoclax Plus '2 + 5' Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

Autor: Huafeng Wang, Yiyi Yao, Liping Mao, Yinjun Lou, Yianlin Ren, Xingnong Ye, Min Yang, Liya Ma, Yi Zhang, Yile Zhou, Xin Huang, Yungui Wang, Huan Xu, Hongyan Tong, Hong-Hu Zhu, Jie Jin
Rok vydání: 2022
Předmět:
Zdroj: Blood. 140:3350-3351
ISSN: 1528-0020
0006-4971
Popis: Background Therapeutic options remain limited for elderly acute myeloid leukemia (AML) considering the poor tolerance to intensive chemotherapy. Venetoclax in combination with modified intensive chemotherapy has been shown achieved significantly improved efficacy in elderly AML patients. Methods We conducted a retrospective study to evaluate the efficacy and safety of venetoclax plus daunorubicin and cytarabine induction chemotherapy (daunorubicin 60mg/m2 days 1–2, intravenously, cytarabine 100mg/m2 days 1–5, intravenously, and venetoclax 100mg day 3, 200mg day 4, 400mg days 5–10, orally, modified DAV regimen) in untreated fit de novo elderly AML. Results Twelve elderly patients who received a modified DAV regimen at our institution were enrolled from March 2021 to June 2022. Eleven of twelve (91.6%) patients achieved complete remission (CR), including 10 patients who achieved CR after one induction cycle and one patient who achieved CR after receiving a second repeated induction cycle. One patient with no response withdrew after one cycle of induction. All patients achieved measurable residual disease negativity detected by muti-parameter flow cytometry in responders. The median follow-up was 108 days. The median event-free survival (EFS) and overall survival (OS) were 398 days and not achieved separately, with an estimated 1-year EFS and OS rate of 75.0% and 100%, respectively. The most severe adverse events during induction therapy included 12 neutropenia (100%), 12 thrombocytopenia (100%), 12 anemia (100%), 5 febrile neutropenia (41.7%) and 4 pneumonia (33.3%). Myelosuppression recovered rapidly, without treatment-related deaths. Conclusions Our study showed the encouraging efficacy and good tolerability of the modified DAV regimen in untreated fit elderly AML patients.
Databáze: OpenAIRE
Externí odkaz: